## Amendments to the Claims:


1. (Previously Amended) A method for treating cancer with a combination therapy, comprising:

administering to a patient suffering from cancer a DNA methylation inhibitor at a dose ranging from 1 to 50 mg/m<sup>2</sup> per day, in combination with a therapeutically effective amount of histone deacetylase inhibitor.

- 2. (Canceled)
- 3. (Withdrawn)
- (Currently Amended) The method according to claim 1, wherein the cancer is selected 4. from the group consisting of breast cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, brain cancer, cancer of the larynx, gallbladder, pancreas, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, colon, stomach, bronchi, kidneys, basal cell carcinoma, squamous cell carcinoma of both ulcerating and papillary type, metastatic skin carcinoma, osteo sarcoma, Ewing's sarcoma, veticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung tumor, gallstones gallstone tumor, islet cell tumor, primary brain tumor, acute and chronic lymphocyctic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuronms, interstinal ganglloneuromas, hyperplastic corneal nerve tumor, marfanoid habitus tumor, Wilm's tumor, seminoma, ovarian tumor, leiomyomater tumor, cervical dysplasia and in situ carcinoma, neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion, mycosis fungoide, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic and other sarcoma, malignant hypercalcemia, renal cell tumor, polycythemia vera, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, and epidermoid carcinomas.
- 5. (Withdrawn)
- 6. (Original) The method of claim 1, wherein the DNA methylation inhibitor is a cytidine analog.
- 7. (Original) The method of claim 6, wherein the cytidine analog is decitabine.



- (Original) The method of claim 1, wherein the histone deacetylase inhibitor is selected 8. from the group consisting of hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
- (Original) The method of claim 8, wherein the hydroxamic acid is selected from the 9. group consisting of trichostatin A, suberoylanilide hydroxamic acid, oxamflatin, suberic bishydroxamic acid, m-carboxy-cinnamic acid bishydroxamic acid, and pyroxamide.
- (Original) The method of claim 8, wherein the cyclic peptide is selected from the group 10. consisting of trapoxin A, apicidin and FR901228.
- (Original) The method of claim 8, wherein the benzamide is MS-27-275. 11.
- (Original) The method of claim 8, wherein the butyrate selected from the group consisting 12. of butyric acid, phenylbutyrate and arginine butyrate.
- (Original) The method of claim 1, wherein administering to the patient includes 13. administering the DNA methylation inhibitor and the histone deacetylase inhibtor orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, or intrathecally.
- 14. (Original) The method of claim 1, wherein the DNA methylation inhibitor is decitabine and is administered intravenously or subcutaneously.
- 15. (Canceled)
- (Original) The method of claim 14, wherein decitabine is administered to the patient via 16. an intravenous infusion per day at a dose ranging from 2 to 50 mg/m<sup>2</sup>.
- (Original) The method of claim 14, wherein decitabine is administered to the patient via 17. an intravenous infusion per day at a dose ranging from 5 to 20 mg/m<sup>2</sup>.





- 19. (Original) The method of claim 1, wherein the histone deacetylase inhibitor is depsipeptide and administered intravenously.
- 20. (Currently Amended) The method of claim 19, wherein depsipeptide is administered to a patient by continuous intravenous infusion for at least 4 hours per day for a week at a dose preferably ranging from 2 to 100 mg/m<sup>2</sup>.
- 21. (Currently Amended) The method of claim 19, wherein depsipeptide is administered to a patient by continuous intravenous infusion for at least 4 hours per day for a week at a dose preferably ranging from 5 to 50 mg/m<sup>2</sup>.
- 22. (Currently Amended) The method of claim 19, wherein depsipeptide is administered to a patient by continuous intravenous infusion for at least 4 hours per day for a week at a dose preferably ranging from 5 to 15 mg/m<sup>2</sup>.
- 23. (Original) The method of claim 1, wherein the histone deacetylase inhibitor is phenylbutyrate and administered intravenously.
- 24. (Original) The method of claim 23, herein phenylbutyrate is administered to the patient by continuous intravenous infusion for at least 2 to 3 weeks at a dose ranging from 100-2000 mg/m<sup>2</sup>.
- 25. (Original) The method of claim 23, wherein phenylbutyrate is administered to the patient by continuous intravenous infusion for at least 2 to 3 weeks at a dose ranging from 250-1000 mg/m<sup>2</sup>.
- 26. (Original) The method of claim 23, wherein phenylbutyrate is administered to the patient by continuous intravenous infusion for at least 2 to 3 weeks at a dose ranging from 500-800 mg/m<sup>2</sup>.
- 27. (Original) The method of claim 1, wherein the DNA methylation inhibitor is administered prior to the administration of the histone deacetylase inhibitor.
- 28. (Currently Amended) The method of claim 1, further comprising administering one or more anti-neoplastic agent selected from the group consisting of alkylating agent, antibiotic agent, retinoid, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biologic agent.

184

- 29. (Withdrawn)
- 30. (Original) The method of claim 28, wherein the antibiotic agent is selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin and anthracenedione, mitomycin C, bleomycin, dactinomycin, and plicatomycin.
- 31-38 (Withdrawn)
- 39-43 (Cancelled)